NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

CEO

Mr. Michael S. Richman MSBA

Employees

Country

ISIN

US65343E1082

WKN

000A2PHHE

Listings

0 Comments

Share your thoughts

FAQ

What is Nextcure stock price today?▼

The current price of 2US.F is €0.39 EUR — it has increased by +0% in the past 24 hours. Watch Nextcure stock price performance more closely on the chart.

What is Nextcure stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Nextcure stocks are traded under the ticker 2US.F.

What is Nextcure revenue for the last year?▼

Nextcure revenue for the last year amounts to 0 EUR.

What is Nextcure net income for the last year?▼

2US.F net income for the last year is -51.79M EUR.

How many employees does Nextcure have?▼

As of April 01, 2026, the company has 43 employees.

In which sector is Nextcure located?▼

Nextcure operates in the Health Care sector.

When did Nextcure complete a stock split?▼

Nextcure has not had any recent stock splits.

Where is Nextcure headquartered?▼

Nextcure is headquartered in Beltsville, US.